EA202192738A1 - Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos - Google Patents
Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolosInfo
- Publication number
- EA202192738A1 EA202192738A1 EA202192738A EA202192738A EA202192738A1 EA 202192738 A1 EA202192738 A1 EA 202192738A1 EA 202192738 A EA202192738 A EA 202192738A EA 202192738 A EA202192738 A EA 202192738A EA 202192738 A1 EA202192738 A1 EA 202192738A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- protein
- aiolos
- ikaros
- tricyclic compounds
- compounds providing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Описаны трициклические связывающие цереблон молекулы для разрушения белка Ikaros или белка Aiolos посредством убиквитин-протеасомного пути для терапевтических применений.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962833107P | 2019-04-12 | 2019-04-12 | |
PCT/US2020/027678 WO2020210630A1 (en) | 2019-04-12 | 2020-04-10 | Tricyclic degraders of ikaros and aiolos |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202192738A1 true EA202192738A1 (ru) | 2022-03-17 |
Family
ID=72750851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202192738A EA202192738A1 (ru) | 2019-04-12 | 2020-04-10 | Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos |
Country Status (14)
Country | Link |
---|---|
US (2) | US11407732B1 (ru) |
EP (1) | EP3953332A4 (ru) |
JP (1) | JP2022527216A (ru) |
KR (1) | KR20210152515A (ru) |
CN (1) | CN113677664A (ru) |
AU (1) | AU2020272978A1 (ru) |
BR (1) | BR112021019669A2 (ru) |
CA (1) | CA3130469A1 (ru) |
EA (1) | EA202192738A1 (ru) |
IL (1) | IL287116A (ru) |
MA (1) | MA55628A (ru) |
MX (1) | MX2021012524A (ru) |
SG (1) | SG11202109024YA (ru) |
WO (1) | WO2020210630A1 (ru) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3679026A1 (en) | 2017-09-04 | 2020-07-15 | C4 Therapeutics, Inc. | Glutarimide |
EP3848371A4 (en) * | 2018-09-07 | 2022-06-08 | Medshine Discovery Inc. | TRICYCLIC FURAN-SUBSTITUTED PIPERIDONEE COMPOUND |
WO2021168314A1 (en) | 2020-02-21 | 2021-08-26 | Plexium, Inc. | Quinazolinone compounds and related compounds |
CA3173658A1 (en) * | 2020-08-07 | 2022-02-10 | C4 Therapeutics, Inc. | Advantageous therapies for disorders mediated by ikaros or aiolos |
JP2023545508A (ja) * | 2020-10-14 | 2023-10-30 | シーフォー セラピューティクス, インコーポレイテッド | Ikzf2又はikzf4を分解する三環式リガンド |
KR20230107570A (ko) * | 2020-10-14 | 2023-07-17 | 씨4 테라퓨틱스, 인코포레이티드 | 표적화 단백질의 분해를 위한 트리시클릭 이종이관능성 화합물 |
CA3217417A1 (en) | 2021-05-05 | 2022-11-10 | Kevin M. Guckian | Compounds for targeting degradation of bruton's tyrosine kinase |
WO2023283130A1 (en) | 2021-07-04 | 2023-01-12 | Newave Pharmaceutical Inc. | Isoquinoline derivatives as mutant egfr modulators and uses thereof |
EP4367113A1 (en) | 2021-07-07 | 2024-05-15 | Biogen MA Inc. | Compounds for targeting degradation of irak4 proteins |
EP4366834A1 (en) | 2021-07-07 | 2024-05-15 | Biogen MA Inc. | Compounds for targeting degradation of irak4 proteins |
AU2022335547A1 (en) * | 2021-08-27 | 2024-04-04 | Hangzhou Glubio Pharmaceutical Co. Ltd. | Isoindolinone compound and use thereof |
TW202322799A (zh) * | 2021-10-06 | 2023-06-16 | 美商C4醫藥公司 | 冠狀病毒非結構性蛋白3降解化合物 |
WO2023061478A1 (zh) * | 2021-10-15 | 2023-04-20 | 先声再明医药有限公司 | 三环类化合物 |
WO2023154417A1 (en) * | 2022-02-09 | 2023-08-17 | C4 Therapeutics, Inc. | Morphic forms of cft7455 and methods of manufacture thereof |
WO2024073507A1 (en) | 2022-09-28 | 2024-04-04 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
CN116120261B (zh) * | 2022-11-30 | 2024-01-23 | 浙大宁波理工学院 | 一种3-[(4-磺胺哌嗪-1-基)甲基]苯甲酸类化合物的制备方法 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US6504034B2 (en) * | 2001-01-23 | 2003-01-07 | Hoffmann-La Roche Inc. | Naphthostyrils |
US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
NZ575061A (en) | 2006-08-30 | 2011-10-28 | Celgene Corp | 5-substituted isoindoline compounds |
US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
US8648096B2 (en) | 2006-09-15 | 2014-02-11 | Celgene Corporation | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
HUE026827T2 (en) | 2006-09-26 | 2016-07-28 | Celgene Corp | 5-substituted quinazolinone derivatives as anticancer agents |
AR065810A1 (es) | 2007-03-20 | 2009-07-01 | Celgene Corp | Derivados de isoindolina 4'-o-sustituidos,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer y en otros trastornos donde es necesario el control de la angiogenesis o la inhibicion de citoquinas, incluyendo tnf-alfa. |
MY157495A (en) | 2007-09-26 | 2016-06-15 | Celgene Corp | 6-,7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same |
US20090298882A1 (en) | 2008-05-13 | 2009-12-03 | Muller George W | Thioxoisoindoline compounds and compositions comprising and methods of using the same |
RU2527952C2 (ru) | 2008-10-29 | 2014-09-10 | Селджин Корпорейшн | Изоиндолиновые соединения для применения при лечении рака |
WO2012175481A1 (en) | 2011-06-20 | 2012-12-27 | Institut Curie | Compositions and methods for treating leukemia |
RU2666530C2 (ru) | 2012-01-12 | 2018-09-11 | Йейл Юниверсити | Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы |
CA3206268A1 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
CN111662226B (zh) * | 2015-01-28 | 2022-03-18 | 中国科学院广州生物医药与健康研究院 | 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物 |
RU2730500C2 (ru) | 2016-01-14 | 2020-08-24 | Канпу Биофармасьютикалз, Лтд | Производное хиназолинона, способ его получения, фармацевтическая композиция и применения |
WO2017197056A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
WO2017201069A1 (en) | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Oxoindoline derivatives as protein function modulators |
JP7048106B2 (ja) | 2016-12-16 | 2022-04-05 | カンプ・バイオファーマスーティカルズ、リミテッド | 組み合わせ、その用途及び処置方法 |
KR102125661B1 (ko) | 2017-02-13 | 2020-06-22 | 강푸 바이오파마슈티칼즈 리미티드 | 전립선암 치료용 조합, 약학 조성물 및 치료 방법 |
EP3590924B1 (en) | 2017-02-28 | 2021-10-27 | Kangpu Biopharmaceuticals, Ltd. | Novel isoindoline derivative, and pharmaceutical composition and application thereof |
WO2019014100A1 (en) | 2017-07-10 | 2019-01-17 | Celgene Corporation | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF |
TWI793151B (zh) * | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
JP2021512153A (ja) | 2018-01-26 | 2021-05-13 | イエール ユニバーシティ | タンパク質分解のイミド系モジュレーターおよび使用方法 |
CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
CA3101338A1 (en) | 2018-06-13 | 2019-12-19 | Biotheryx, Inc. | Aminoamide compounds |
EP3813834A4 (en) | 2018-06-29 | 2022-03-09 | Dana Farber Cancer Institute, Inc. | NEW CRBN MODULATORS |
EP3814380A4 (en) | 2018-06-29 | 2022-06-15 | Dana Farber Cancer Institute, Inc. | BI-SPECIFIC DEGRADING AGENTS |
US20210284624A1 (en) | 2018-06-29 | 2021-09-16 | Dana-Farber Cancer Institute, Inc. | Immunomodulatory compounds |
WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
US11192877B2 (en) | 2018-07-10 | 2021-12-07 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CN114641337A (zh) | 2019-08-27 | 2022-06-17 | 密歇根大学董事会 | Cereblon e3连接酶抑制剂 |
WO2021127586A1 (en) | 2019-12-20 | 2021-06-24 | Calico Life Sciences Llc | Protein tyrosine phosphatase degraders and methods of use thereof |
-
2020
- 2020-04-10 WO PCT/US2020/027678 patent/WO2020210630A1/en active Application Filing
- 2020-04-10 MA MA055628A patent/MA55628A/fr unknown
- 2020-04-10 KR KR1020217036582A patent/KR20210152515A/ko unknown
- 2020-04-10 AU AU2020272978A patent/AU2020272978A1/en active Pending
- 2020-04-10 CN CN202080028010.XA patent/CN113677664A/zh active Pending
- 2020-04-10 CA CA3130469A patent/CA3130469A1/en active Pending
- 2020-04-10 MX MX2021012524A patent/MX2021012524A/es unknown
- 2020-04-10 SG SG11202109024YA patent/SG11202109024YA/en unknown
- 2020-04-10 JP JP2021559999A patent/JP2022527216A/ja active Pending
- 2020-04-10 EP EP20788335.6A patent/EP3953332A4/en active Pending
- 2020-04-10 BR BR112021019669A patent/BR112021019669A2/pt unknown
- 2020-04-10 EA EA202192738A patent/EA202192738A1/ru unknown
-
2021
- 2021-10-10 IL IL287116A patent/IL287116A/en unknown
- 2021-10-11 US US17/498,617 patent/US11407732B1/en active Active
-
2022
- 2022-04-18 US US17/723,199 patent/US20230082430A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230082430A1 (en) | 2023-03-16 |
EP3953332A1 (en) | 2022-02-16 |
JP2022527216A (ja) | 2022-05-31 |
BR112021019669A2 (pt) | 2021-12-07 |
EP3953332A4 (en) | 2023-06-14 |
WO2020210630A1 (en) | 2020-10-15 |
KR20210152515A (ko) | 2021-12-15 |
AU2020272978A1 (en) | 2021-09-16 |
CA3130469A1 (en) | 2020-10-15 |
US11407732B1 (en) | 2022-08-09 |
SG11202109024YA (en) | 2021-09-29 |
IL287116A (en) | 2021-12-01 |
MX2021012524A (es) | 2021-11-12 |
CN113677664A (zh) | 2021-11-19 |
MA55628A (fr) | 2022-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202192738A1 (ru) | Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos | |
CY1123746T1 (el) | Ανθρωποποιημενα tau αντισωματα σε νοσο του alzheimer | |
EA201992546A1 (ru) | Средства на основе антител к cd33 | |
EA201790288A1 (ru) | Анти-ctla4 моноклональное антитело или его антигенсвязывающий фрагмент, фармацевтическая композиция и применение | |
EA202091964A1 (ru) | КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
JOP20200074A1 (ar) | أجسام مضادة ضد tau واستخداماتها | |
PH12020552229A1 (en) | Il-11ra antibodies | |
EA200901313A1 (ru) | Ингибиторы тирозинкиназы брутона | |
BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
CY1124153T1 (el) | Αντισωματα και πολυπεπτιδια που κατευθυνονται εναντι cd127 | |
CY1120095T1 (el) | Αναστολεις της erk και μεθοδοι χρησης | |
EA201991029A1 (ru) | Ингибиторы magl | |
EA201992083A1 (ru) | Модуляторы соматостатина и их применения | |
EA202091350A1 (ru) | Связывающие молекулы, специфично связывающиеся с тау-белком | |
ATE437185T1 (de) | Gegen das gemeinsame epitop von mutierten p53 gerichtete humane synthetische einzelkettenantikörper und anwendungen davon | |
EA201992281A1 (ru) | Связывающие молекулы, специфично связывающиеся с тау-белком | |
BR112021019070A2 (pt) | Ligantes de pseudoquinase tyk2 | |
EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
EA201991876A1 (ru) | Антитела против фактора d и их применения | |
EA202191769A1 (ru) | Тубулизины и конъюгаты белок-тубулизин | |
BR112022008821A2 (pt) | Ligantes de pseudoquinase tyk2 | |
BR112022000855A2 (pt) | Moduladores de nlrp3 | |
MX2020008115A (es) | Glucuronilacion como una nueva modificacion postraduccional acida en anticuerpos monoclonales terapeuticos. |